Wegovy obesity drug could reach Brazil's public health system by 2026

Novo Nordisk submitted Wegovy, a high-dose semaglutida injection, to Brazil's health technology commission in mid-December 2024, hoping to make the obesity drug available through the country's public health system. The company is targeting a specific population: people over 45 with established cardiovascular disease but no diabetes diagnosis. If all goes according to schedule, the drug could reach patients by mid-2026—though that timeline depends on regulatory approval, budget negotiations, and the machinery of public procurement.

The regulatory process itself is a waiting game measured in business days. Brazil's Conitec commission has 180 business days to evaluate the request, a clock that started ticking on December 17, 2024. That deadline falls on August 28, 2025. But the commission can extend its review by another 90 business days if needed, pushing a final decision into early January 2026. Even if Wegovy clears that hurdle, the approval is only half the battle. Once the decision is published in the official gazette, the government gets another 180 business days to negotiate prices, arrange supply chains, and write the clinical protocols that will guide doctors on how to prescribe it. Depending on which timeline holds, the drug could be available to the public as early as June 2026 or as late as September 2026.

Right now, as of March 2025, the Conitec evaluation should be entering its detailed technical phase. The commission should be drafting its recommendation report and preparing for a public consultation period. Yet the drug has not appeared on the commission's public portal among active consultations, suggesting the process may be moving slower than the calendar suggests.

Currently, Brazil's public health system treats obesity through non-pharmaceutical means: diet, exercise, psychological support, and bariatric surgery for severe cases. Wegovy would represent the first injectable medication option available through SUS, a significant shift in how the system approaches a condition that affects millions of Brazilians. The drug works by mimicking a hormone that regulates appetite, helping patients feel fuller longer and eat less.

Novo Nordisk was careful to clarify what it is not doing. The company has not filed requests to add Ozempic or Rybelsus—two other semaglutida products it manufactures—to the public system. Both drugs are approved in Brazil only for type 2 diabetes treatment, even though they contain the same active ingredient as Wegovy. The company issued a statement saying it does not endorse off-label use of its medications and recommends all treatment occur under medical supervision.

This is not the first time Novo Nordisk has tried to bring an obesity drug into Brazil's public system. In 2023, the company submitted Saxenda, a lower-dose liraglutida injection, for the same purpose. That application stalled due to budget constraints, even though the technical evaluation found the drug viable. Saxenda is now available in four states—Goiás, Distrito Federal, Rio de Janeiro, and Espírito Santo—through state programs or specialized centers. In São Paulo, two major hospitals offer it using their own funds. The Conitec says Saxenda is still under review and should reach a decision around the same time as Wegovy.

The real question is whether the federal government will find room in its budget for a new obesity medication. Brazil's health system is perpetually stretched, and adding a drug that requires ongoing injections and medical monitoring is not a trivial expense. But obesity is also a growing public health burden, and the current toolkit—lifestyle changes and surgery—reaches only a fraction of those who need help. If Wegovy wins approval, it could offer an option to people who fall between those two poles: those whose weight threatens their health but who are not yet candidates for surgery.